Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Burst CME™ for the Onco-Nurse: Optimizing Application of Targeted Therapies for HR+ Breast Cancer

Release Date: October 15, 2020
Expiration Date: October 15, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview of the safety and efficacy of targeted therapies, specifically cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway inhibitors, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. This activity also includes evidence-based strategies to effectively manage adverse effects associated with targeted therapies and effective counseling strategies for patients who maybe be candidates for these therapies. The engaging, multimedia format of this program integrates audio commentary from an expert thought leader with various text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward advanced nurse practitioners, nurses, and other healthcare professionals interested in the multidisciplinary treatment and management of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline recent safety and efficacy data pertaining to the application of CDK4/6 and PI3K inhibitors in the setting of HR+ breast cancer
  • Develop evidence-based strategies to effectively manage adverse events associated with targeted therapies for treatment of HR+ breast cancer
  • Review effective counseling strategies for patients with breast cancer who may be candidates for CDK4/6 and PI3K inhibitors

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Amber P. Potter, DNP, APRN, FNP-C, CBCN
Amber P. Potter, DNP, APRN, FNP-C, CBCN
Family Nurse Practitioner
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic
Breast Medical Oncology Department
The University of Texas MD Anderson Cancer Center
Houston, TX

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By